|Videos|October 11, 2021
GenesisCare physicians discuss PSMA-PET imaging agent Pylarify
Advertisement
GenesisCare doctors Kishore K. Dass, MD, Anurag Agarwal, MD, and Jerry Singer, MD, share their expert insight on the novel PSMA-PET imaging diagnostic Pylarify (piflufolastat F 18), which is FDA approved for use in patients with prostate cancer. The first US patient to receive Pylarify was treated at the GenesisCare facility in Boca Raton, Florida, where these doctors work.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5







